Kardigan is currently untradeable in this screen due to a data outage on its price feed, and what data is available shows weak fundamental quality and a speculative, binary biotech profile with no identified trading edge.
Thesis pillars
- No Price Data Available↑Improving
- Weak Quality Piotroski Score→Stable
- Binary Biotech Speculative Classification→Stable
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 5, 2026· older than 90 days
Kardigan, Inc. (KARD) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $15.56: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 8.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality.
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary... Read more
Sell if holding. Engine safety override at $15.56: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 8.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.8/10, moderate confidence.
Passes 8/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst cluster(5), earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated Nov 4, 2026Recent Developments — Kardigan, Inc.
Latest news
- NEWS HC Wainwright Initiates Coverage on Kardigan With Buy Rating — fiscal.ai Nov 4, 2026 positive
- NEWS This Lockheed Martin Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday — benzinga Nov 4, 2026 positive
- NEWS HC Wainwright & Co. Initiates Coverage On Kardigan with Buy Rating, Announces Price Target of $42 — benzinga Nov 4, 2026 positive
- NEWS Cantor Fitzgerald Initiates Coverage on Kardigan, Inc. with Overweight Rating — fiscal.ai Oct 29, 2026 positive
- NEWS This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday — benzinga Oct 29, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T11:44:08Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.56: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 8.6:1 is above the 1.5:1 BUY gate. Specifically: Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $14.47. Score 5.8/10, moderate confidence.
Analyst target: $35.67 (+129.2% upside). Prior stop was $14.47. Stop-loss: $14.47.
Quality below floor (2.5 < 4.0); Value-trap signals (2/5): Margin compression (op margin -5.0%), Material insider selling (21 sells, 5.34% of cap).
Kardigan, Inc. trades at a P/E of N/A (forward -3.8). TrendMatrix value score: 9.0/10. Verdict: Sell.
14 analysts rate KARD, with a consensus score of 4.4/5. 7 analysts publish price targets averaging $41.
What does Kardigan, Inc. do?Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The...
Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey.